Abstracts tagged "Clinical practice guidelines"

Abstract Number: 1699 • ACR Convergence 2020
Training Residents to ‘Choose Wisely’ When Testing for Antinuclear Antibodies
Iman Qaiser¹, Tracy Koehler¹ and Richard Martin², ¹Mercy Health Saint Mary's, Grand Rapids, MI, ²Michigan State University College of Human Medicine, Grand Rapids, MI
Background/Purpose: In many hospitals residents are the first providers to evaluate new patients. Consequently, residents often initiate the work-up of newly admitted patients. Multiple studies…
Abstract Number: 1741 • ACR Convergence 2020
Does Preventive Care Matter? (in RA)
Morgan Greenwald¹, JoAnn Ball¹, Shannon Lopez¹, Monica Berg¹ and Maria Greenwald¹, ¹Desert Medical Advances, Palm Desert, CA
Background/Purpose: Preventive medical care improves morbidity and mortality. The assessment included 28,105 RA patients from prospective randomized trials.Methods: Nested data from a single site was…
Abstract Number: 051 • 2020 Pediatric Rheumatology Symposium
Pediatric Providers’ Perspectives on Suspected Immune-Mediated Diffuse Alveolar Hemorrhage and Clinical Care Pathways
Jessica Bloom¹ and Robert Fuhlbrigge ², ¹Children's Hospital Colorado, Aurora, Colorado, ²University of Colorado, Aurora
Background/Purpose: Immune-mediated diffuse alveolar hemorrhage (iDAH) is a life-threatening complication of pediatric rheumatologic diseases such as vasculitis, systemic lupus erythematosus, and antiphospholipid antibody syndrome. Delay…
Abstract Number: 175 • 2020 Pediatric Rheumatology Symposium
Application of Juvenile Idiopathic Arthritis Treatment Guidelines and Factors Associated with Increased Likelihood of Intra-articular Corticosteroid Administration
Erin Balay¹, Jennifer Weiss ², Y. Ingrid Goh ³, Nathan Rubin ⁴ and Danielle Bullock ⁴, ¹University of Minnesota, saint paul, ²Hackensack University Medical Center, Hackensack, ³The Hospital for Sick Children, Toronto, Canada, ⁴University of Minnesota, Minneapolis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood disease which can result in debilitating arthritis. The 2011 ACR JIA treatment guidelines recommend intra-articular corticosteroid…
Abstract Number: 191 • 2020 Pediatric Rheumatology Symposium
Utilization of Telemedicine in Pediatric Rheumatologic Care
Rajdeep Pooni¹ and Tzielan Lee ¹, ¹Stanford Children's, Palo Alto
Background/Purpose: Telemedicine has the potential for improving access to care, particularly for pediatric patients with complex needs in remote or rural locations. Previous studies have…
Abstract Number: 263 • 2019 ACR/ARP Annual Meeting
Health Professionals Agreed with Recommendations to Evaluate and Optimize Adherence to Disease-modifying Treatments, but Perceived Feasibility Was Lower: A Study of 357 Physicians and Health Professionals in France
Laure Gossec¹, Anna Moltó ², Catherine Beauvais ³, Eric Senbel ⁴, René-Marc Flipo ⁵, Sophie Pouplin ⁶, Christophe Richez ⁷, Alain Saraux ⁸, Philippe Gaudin ⁹, Daniel WENDLING ¹⁰ and Maxime Dougados ¹¹, ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ³Paris St Antoine University Hospital, Paris, France, ⁴Rheumtologist Private Practice, Marseille, France, ⁵University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France, ⁶Rouen University Hospital, Rouen, France, ⁷Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ⁸CHU de la Cavale-Blanche Brest, Brest, France, ⁹Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, ¹⁰Rheumatology, University Teaching Hospital (CHRU), Besançon, France, ¹¹Cochin Hospital, Paris, France
Background/Purpose: In chronic inflammatory rheumatic diseases (CIRDs), including rheumatoid arthritis, spondyloarthritis, connective tissue diseases and crystal-induced arthritis, long-term adherence to disease-modifying drugs (DMARDs) is only…
Abstract Number: 320 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution
Rebecca Overbury¹, Jakrapun Pupaibool ², Christopher Hansen ³, Daniel Clegg ⁴ and Dorota Lebiedz-Odrobina ⁵, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah, Division of Infectious Diseases, Salt Lake City, UT, ³University of Utah, Department of Dermatology, Salt Lake City, UT, ⁴University of Utah, Salt Lake City, UT, ⁵University of Utah, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Research has shown potential retinal toxicity rates from HCQ as high as 7.5%. Research suggests toxicity is dose-related. In 2016, the American Academy of…
Abstract Number: 1188 • 2018 ACR/ARHP Annual Meeting
Are Residents Choosing Wisely? Analysis of Adherence to Recommendations of Ordering Anti-Nuclear Antibody Testing in an Internal Medicine Residency Primary Care Clinic
Aparna Das, Rajarajan Panneerselvan, Annum Faisal, Jubran Rind and Rima Shah, Internal medicine, Michigan state university, grand rapids, MI
Background/Purpose: A positive anti-nuclear antibody (ANA) is considered very useful for the diagnosis of SLE and systemic sclerosis, and somewhat useful for the diagnosis of…
Abstract Number: 2634 • 2018 ACR/ARHP Annual Meeting
The Risk of Hydroxychloroquine Retinopathy in an SLE Cohort: Screening and Prevention in Clinical Practice
Caroline Siegel¹, Jennifer M. Grossman², John Fitzgerald³, Bevra H Hahn⁴, Sarah Chen⁵, Lori Sahakian⁴, Eloise Olmos², Michael B. Gorin⁶ and Maureen A. McMahon², ¹Department of Internal Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication for SLE because of its highly favorable risk-benefit ratio. Drug-induced retinopathy is one of very few serious…
Abstract Number: 2395 • 2017 ACR/ARHP Annual Meeting
Recommendations on the Management of Rheumatoid Arthritis in Patients with Cancer: A Systematic Review of Clinical Practice Guidelines and Consensus Statements
Maria A. Lopez-Olivo¹, Ines Colmegna², Aliza Matusevich¹, Susan Ruyu Qi³, Natalia Zamora¹, Robin Sharma¹, Gregory Pratt⁴ and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Division of Rheumatology, Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada, ³Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada, Montreal, QC, Canada, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: To compare the recommendations of clinical practice guidelines (CPGs) and consensus statements (CSs) regarding the management of rheumatoid arthritis (RA) in patients with cancer.…
Abstract Number: 2469 • 2016 ACR/ARHP Annual Meeting
How Rheumatoid Arthritis Patients and Rheumatologists Communicate during Clinic Visits When a New DMARD Is Prescribed
Lorie L. Geryk¹, Susan J. Blalock², Courtney A. Roberts², Beth L. Jonas³ and Delesha M. Carpenter⁴, ¹Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Chapel Hill, NC, ²Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, ³Thurston Arthritis Research Ct, University of North Carolina Thruston Arthritis Research Center, Chapel Hill, NC, ⁴Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Asheville, NC
Background/Purpose: This observational study includes data from clinic visits of 38 RA patients (3 rheumatologists) that occurred in a southeastern state from May 2014 to…
Abstract Number: 1424 • 2015 ACR/ARHP Annual Meeting
Barriers to Primary Care Clinician Adherence to Clinical Guidelines for the Management of Low Back Pain: A Systematic Review and Meta-Synthesis of Qualitative Studies
Susan Slade¹, Peter Kent², Shilpa Patel³, Tracey Bucknall⁴ and Rachelle Buchbinder¹, ¹Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Melbourne, Australia, ²Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark, ³Warwick Clinical Trials Unit, The University of Warwick, Warwick, United Kingdom, ⁴School of Nursing & Midwifery, Deakin University and Alfred Health, Melbourne, Australia
Background/Purpose: Low back pain is the highest ranked condition contributing to years lived with disability according to the most recent Global Burden of Disease study…
Abstract Number: 1488 • 2015 ACR/ARHP Annual Meeting
Following the American College of Rheumatology Quality Guidelines Can Enhance the Safety of Rheumatoid Arthritis Patients Treated with Disease Modifying Drugs
Delfina Bur¹ and Humeira M. Badsha², ¹Dr. Humeira Badsha Medical Clinic, Dubai, United Arab Emirates, ²Rheumatology, Dr Humeira Badsha Medical Center, Dubai, United Arab Emirates
Background/Purpose: Adverse events (AEs) and serious adverse events (SAEs) from disease modifying drugs (DMARDs) for Rheumatoid Arthritis (RA) can result in significant morbidity and even…
Abstract Number: 1982 • 2013 ACR/ARHP Annual Meeting
Development and Validation Of Medication Assessment Tools Specific For Rheumatoid Arthritis
Louise Grech^1,2, Bernard Coleiro^1,3, Anthony Serracino Inglott¹, Lilian M. Azzopardi¹, Victor Ferrito¹ and Andrew A. Borg^3,4, ¹Pharmacy, University of Malta, Msida, Malta, ²Clinical Pharmacy, Mater Dei Hospital, Msida, Malta, ³Medicine, Mater Dei Hospital, Msida, Malta, ⁴Medicine, University of Malta, Msida, Malta
Background/Purpose: Medication assessment tools can be defined as evidence-based instruments intended for the evaluation of prescribing trends and monitoring of adherence to established guidelines. Medication…
Abstract Number: 1000 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Cost-Effectiveness Of The Treatment Strategies With and Without Biological Response Modifiers For Patients With Recently Diagnosed Rheumatoid Arthritis Following A Clinical Guideline For Treatment Selection
An Tran-Duy¹, Annelies Boonen², Wietske Kievit³, Piet L.C.M. van Riel⁴, Mart A.F.J. van de Laar⁵ and Johan L. Severens⁶, ¹Department of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, ⁶Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands
Background/Purpose: In clinical practice, management of rheumatoid arthritis (RA) is characterized by a sequence of drugs which is determined based on patient characteristics, notably disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].